New PET radiotracer for prostate cancer found to be safe and effective

February 3, 2017

In the latest issue of The Journal of Nuclear Medicine, researchers have confirmed that a new PET radio tracer for diagnosing primary and metastatic prostate cancer is safe and effective.

The gallium-68-labeled peptide BBN-RGD agent targets both gastrin-releasing peptide receptor and integrin αvβ3. Unlike single-receptor targeting, dual-receptor targeting allows for tumor contrast when either or both receptor types are expressed.

Read the full article